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ABSTRACT 
Objective: The study aimed to formulate standardized polysaccharide fraction of Noni (SPFN) fruit into syrup preparations to fulfill the 
acceptability requirement of National Agency of Drugs and Food Control [Badan Pengawas Obat dan Makanan Republik of Indonesia (BPOM RI)] so 
that it can be used in the community as an immunostimulant.  
Methods: The optimization of the formula A and B were done using Simplex Lattice Design (SLD) method and its stability tested under extreme 
temperature change effect using thaw cycling method by evaluating the physical properties, microbial contamination and immunostimulant activity. 
MTT method was used to determine the immunostimulant activity of syrup against lymphocyte proliferation in vitro.  
Results: Based on the results of stability tests of formula A using pH (4.45), viscosity (81.03 mPas), taste (good taste), pouring power (2.31 s), 
amount of bacteria (68 colonies/ml), total yeast and mold (269 colonies/ml) parameters and fulfilled the acceptability requirement of BPOM RI. 
Formula A could maintain better stability than formula B. Formula A syrup used for immunostimulant activity testing that could increase 
lymphocyte proliferation at a concentration of 13.33 to 106.64 μg/μl and it’s stable under the influence of extreme temperature changes.  
Conclusion: Formula A could be used to produce SPFN syrup, which has stable physical properties and immunostimulant activity beside no 
microbial contamination that fulfill requirements of BPOM RI.  
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The stability of syrup during storage was expected to influence 
immunostimulant activity. Some previous researches related to these 
topic have been done for example; influence of Morinda citrifolia L. 
fruit extract as adjuvant on IgY production raised in laying chickens 
against avian influenza [19], optimization of polysaccharide-rich 
fractionation from Morinda citrifolia L., fruit-based on 
immunostimulatory effect in vitro [7], polysaccharide-rich fraction of 
noni fruit (Morinda citrifolia L.) as doxorubicin co-chemotherapy: 
evaluation on catalase, macrophage and TCD8+lymphocyte [20], 
characterization of purified polysaccharide fraction of Morinda 
citrifolia L. Fruit [8] and development of standardized product of 
polysaccharide fraction of noni fruit (Morinda Citrifolia L.). However, 
there is no detail information regarding the optimum formula of the 
syrup to be developed as immunostimulant containing fraction of the 
 are the polymers of monosaccharides and most are 
polymer of glucose [1]. Most of the polysaccharides found in plants 
are high molecular weight polysaccharides which generally have 
immunomodulatory activities [2]. According to several studies, 
polysaccharides can cause various immunomodulatory effects on 
animal tissues, blood, digestive tract and spleen. Polysaccharides 
that taken orally was able to stimulate the immune system in the 
blood of healthy adults [3]. Immunostimulant activity of Morinda 
citrifolia is related to its antitumor activity [4]. Noni fruit 
polysaccharides have antitumor activity against Lewis Lung 
Carcinoma (LLC) in mice by suppressing tumor growth through 
immune system activation [5]. Extract of Morinda citrifolia was able 
to stimulate cannabinoid receptors (CB2) with decreased IL-4 and 
increase IFN-gamma [6]. Noni fruit polysaccharide fraction was 
reported to be able to increase lymphocyte proliferation and 
macrophage phagocytosis in vitro [7]. It has been done the 
standardize of a polysaccharide fraction of Noni fruit (SPFN) 
collected from the district of Yogyakarta, Indonesia with glucose as a 
marker [8]. The use of Noni fruit as an immunostimulant is designed 
to be a pharmaceutical product, so it can be used in the community. 
The solution has to easily distributed and drugs dissolved in a liquid 
carrier. Solid, liquid, gas molecules can be distributed between 
carrier molecules. Syrup that has been dissolved in liquids can 
increase application in the stomach, skin and other administrative 
pathways faster than other dosage forms [9]. Therefore efficacious 
substances are formulated in the form of syrup due to the 
absorption in form of liquids [10]. Syrup preparations contain 
excipients such as preservatives, sweeteners, thickeners and other 
ingredients used to facilitate the route of the preparation, protect or 
improve physical and chemical stability and increase the solubility of 
the active ingredients in preparation [11]. The quality requirements 
for syrup are microbial number (mold/yeast number and total plate 
number) [12] and physical properties. Physical tests for syrup 
preparations include organoleptic, viscosity, ease of pouring and pH. 
Organoleptic test of syrup preparation was carried out using 
questionnaires by 20 respondents. The greater the value (1-4 scale) 
obtained, the better the taste of syrup. Syrup evaluation results 
indicate that syrup has good taste[13, 14]. Syrup preparation must 
have good viscosity and flow properties. The viscosity value has a 
relationship with the pouring value of a liquid. If the viscosity 
decreases, the pouring time is faster, because the fluidity of solution 
is inversely proportional to viscosity [15]. Viscosity values and 
pouring capacity of syrup preparations do not have certain of 
requirements, this evaluation considers the ease of preparation to 
flow from its place, and stability of the preparation. The viscosity 
value of the preparation is 81.03 mPas and the pouring power is 
2.31 seconds. Syrup preparations are designed to have a pH value of 
around 4-6 [16, 17]. This value considers the taste of the preparation 
so that it can be taken orally. Syrup preparation has a pH of around 
4.45, contain excipients such as preservatives, sweeteners, 
thickeners and other ingredients used to facilitate the route of 
preparation, protect or improve physical and chemicals stability and 
increase the solubility of the active ingredients [11] Therefore, it is 
necessary to evaluate formulation of syrup with modification of 
thickening agents. The use of one the thickening agents selected, 
CMC sodium and xanthan gum to obtain more stable formula [18].  
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noni fruit. Furthermore, results of these research will provide benefit 
information for development of the formula.  
MATERIALS AND METHODS 
Materials 
Sample of noni fruits that used was collected from the district of 
Yogyakarta, Indonesia as standardized polysaccharide fraction of 
noni fruit [(SPFN) produced by PT. Phytochemindo Reksa, Bogor, 
Indonesia]. Benzoate sodium, carboxy-methyl-cellulose sodium, 
citric acid, citrate sodium, propylene glycol, sucrose and MTT were 
obtained from Merck. The lymphocyte cells proliferation test 
involved male Balb/C mice, aged of 2-3 mo, weighed of 25-30 g. 
Methods 
Design of the research was experimental research. The manufacture 
of SPFN syrup using two different formulas, then each syrup was 
evaluated. The stability test used Freeze-Thaw Cycling (FTC) method 
for 3 cycles. The syrup parameters were observed by organoleptic, 
pH, viscosity, ease of pouring, yeast mold number and total plate 
number. The most stable syrup was tested its lymphocyte cell 
proliferation using MTT method. 
Preparation of SPFN 
The dried powder of Noni fruit was macerated with 75 °C (1:20 w/v) 
for 30 min the macerate obtained was evaporated and 95% ethanol 
was added for 30 min, then filtered [21]. The fraction obtained was 
dark brown, had a distinctive aroma and taste. Evaluation of 
microbial content showed the fraction fit in the required quality. 
Stability testing  
Stability test was carried out by FTC method for 3 cycles. The 
preparations were stored in a row at freezing temperature (±0 °C) 
for 24 h, room temperature (±30 °C) for 24 h. After melting the 
preparations were stored again at hot temperature (±45 °C) for 24 h 
and room temperature (±30 °C) for 24 h [22]. Syrups will stable 
during the transportation process if it is able to maintain the 
parameters under FTC for 3 cycles. 
Lymphocyte isolation and proliferation assay 
The lymphocyte was isolated from Balb/c mice’s spleen. The Balb/c 
mice (male, aged 2-10 w old, 25-30 g) were purchased from Gadjah 
Mada University Integrated Research and Testing 
Laboratory.[Approval Letter no. 00130/04/lPPT/X/2017]. Animals 
were acclimatized for a period of 24 h to ensure their suitability for 
research. Lymphocyte cells were isolated and suspended into 
complete RMPI medium. The lymphocyte cells suspension of 100 µl 
(2x106
Determination of the dosage of a fraction  
 cells/ml) medium was distributed into 96 wells microplate 
according to the treatment groups. Hepatitis B vaccine was added 10 
µl per well and then incubated in an incubator with 5% CO2 at 37 °C 
for 24 h. The next step was added 100 µl sample of syrup and solution 
of SPFN (as a comparison) in various concentrations and then 
incubated again for 48 h. Solution of 5 mg/ml MTT was added 10 
µl/well and reincubated for 4 h, then 50 µl stop solution (10% SDS in 
0.01N HCl) added, followed by incubation at room temperature in a 
dark place overnight. The Optical Density (OD) value was measured 
using a microplate reader at a wavelength of 550 nm [12]. 
Previous studies showed that SPFN dosage of 25-50 mg/kg body weight 
could increase the number of macrophages that play role in the immune 
system [7]. This study used a dosage of 50 mg/kg body weight for adult 
human. So to prepare 60 ml of syrup was needed of 800 mg SPFN. 
Preparation of syrup 
Syrup polysaccharide fraction of noni fruit (SPFN) was prepared by two 
formulas with the different on thickening agent. Formula A used xanthan 
gum and formula B used CMC sodium as thickening agent (table 1).  
The formulas have been optimized by simplex lattice design method. The 
syrup was prepared by dissolving SPFN and sucrose in warm water. The 
solution SPFN and sucrose was added with propylene glycol, buffer, and 
preservative and then stirred using a mixer. Propylene glycol was used 
as a cosolvent and stabilizing agent [23] for helping the solubility of citric 
acid, sodium citrate and benzoate sodium. Formula A was added with 
xanthan gum as thickener, while formula B was added with CMC sodium, 
then a solution of SPFN and essence was added to each formula. 
 
Table 1: Syrup formulas of a polysaccharide fraction of noni fruit (SPFN) with various thickening agents 
Ingredients  Formula A FFo Formula B 
1. SPFN (1:1) (mg) 800  800  
2. Propylene glycol (%) 5  5  
3. Citric acid (%) 0.2  0.2  
4. Sodium citrate (%) 0.3  0.3  
5. Xanthan gum (%) 0.15  - 
6. CMC sodium (%) - 0.2  
7. Benzoate sodium (%) 0.1  0.1  
8. Sucrose (%) 59.5  47.5  
9. Essence q. s. q. s. 
10. Distilled Water up to (ml) 60  60  
Notes: SPFN (1:1): Mix of SPFN: Lactose = 1: 1 
 
Stability test of the formula syrups 
The two of formula syrups stability were evaluated against 
organoleptic tests by using questionnaires [13]. The stability of both 
formula syrup also was observed against viscosity, ease of pouring, 
pH, microbial, yeast molds and total plate number after receiving the 
freeze-thaw test. The freeze-thaw test was carried out for 3 cycles, 
where the first cycle takes place of 24 h at cold temperatures, 24 h at 
room temperature, 24 h at hot temperatures and back to 24 h at 
room temperature. Every end of the cycle, the formula syrups were 
evaluated to determine its stability [21]. 
Selected formula 
Based on the evaluation of stability test, one optimum syrup was 
selected. The selection based on the results of organoleptic test, 
viscosity test, ease of pouring test, pH test, microbial number test 
and evaluation of stability test for both formulas. 
Lymphocyte cell proliferation test from the selected formula 
The selected formula, then it was tested against lymphocyte cell 
proliferation by MTT Assay. Lymphocyte cells were isolated from 
spleen of Balb/C mice. The lymphocyte cells suspension in the 
100 μl (2 x 106cells/ml) medium was distributed into 96-
microplate well according to the treatment group. For inducing 
immune response was done by adding 10 μl hepatitis B vaccine 
to each well and then incubated for 24 h in an incubator with 5% 
CO 2  at 37 °C. The next step was added 100 µl of syrup in various 
concentration and 100 µl solution of SPFN (as a comparison) and 
then incubated again for 48 h in incubator. Then added 10 µl of 
MTT 5 mg/ml and incubated for 4 h in incubator. After 
incubation, 50 µl of stop solution (10% SDS in 0.01N HCl) was 
added and then incubated at room temperature for 15 min until 
color changes occur. The OD measurements using microplate 
readers by a wavelength of 650 nm. 
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RESULTS 
Results of formula syrup stability test after receiving extreme 
temperature treatment of FTC method 3 cycles. The data obtained 
after the formula A and formula B syrups receiving extreme 
temperature treatment of FTC method for 3 cycles, were showed in 
table 2, fig. 1, 2 and 3. Formula B syrup changed significantly since 
cycle 1, these were characterized by the microbial number (table 2), 
the profile of viscosity (fig. 1), the profile of pH (fig. 2), and the 
profile of pouring power (fig. 3) as the parameters of formula A and 
formula B syrup after receiving FTC method for 3 cycles. Each point 
of fig. 1, 2 and 3 represented as mean±SD (n=4). 
 
Table 2: Microbial number of formula A and B syrup 
 Cycle  Amount of yeast and mold (colonies/ml) Total plate number (colonies/ml) 
 Formula A  Formula B  Formula A  Formula B 
0  440  140  50  100 
1  40  100  80  230 
2  400  60  120  100 
3  60  60  100  10 
mean±SD (Standard deviation), n = 4 
 
 
Fig. 1: The viscosity profile of formula A and formula B syrup mean±SD (Standard deviation), n = 4 
 
 
Fig. 2: The pH profile of formula A and formula B syrup mean±SD (Standard deviation), n = 4 
 
Results of lymphocyte cells proliferation 
The result of lymphocyte cells proliferation obtained from cells was 
cultured with test samples [SPFN solution and the selected formula 
(formula A) of SPFN syrup, briefly as SPFN syrup] for 48 h. Cell viability 
determined using MTT assay. The SPFN solution and SPFN syrup could 
significantly increase lymphocyte cells proliferation (fig. 4). The SPFN 
solution (fig. A) showed a significant increase at concentration 53.32 
μg/μl. The highest level of lymphocyte cell proliferation showed at a 
concentration of 106.64 μg/μl. The results showed an increase of 
lymphocyte cells proliferation affected by the concentration of the SPFN 
solution. Based on the results of statistical analysis, there was no 
significant (p<0.05) difference between the OD of SPFN solution and 
SPFN syrup (fig. 4 B) in the majority of the polysaccharide fraction 
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concentration. Therefore, the SPFN syrup did not affect the 
immunostimulant activity The SPFN solution and SPFN syrup, for 
stability test, both also received extreme temperature treatment of FTC 
method for 3 cycles. The OD values obtained after receiving FTC method 
showed significant differences of SPFN solution at concentration 13.33 
μg/μl; 53.32 μg/μl and 79.98 μg/μl respectively (fig. 5A), while the OD 
values obtained after receiving FTC method of SPFN syrup (fig. 5B) did 
not show a significant differences in all concentrations. 
 
 
Fig. 3: The ease of pouring profile of formula A and formula B syrup mean±SD (Standard deviation), n = 4 
 
 
Fig. 4: Lymphocyte Proliferation profile of SPFN solution (A) SPFN syrup (B), each stem represented as mean±SD (n = 3). *
 
p<0.05 
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The organoleptic tests were to evaluate the acceptability of syrup 
preparations by patients. The optimum syrup of formula A and 
formula B showed that both have a sweet taste, dark brown flavor 
and a distinctive aroma. The viscosity test showed that the average 
viscosity optimum of formula A syrup was 81.03 mPas and average 
viscosity optimum of formula B syrup was 67.95 mPas. The greater 
amount of sucrose and thickeners, the greater viscosity of syrup, but 
the viscosity in this study is dominated by sucrose. Xanthan gum and 
CMC sodium have different thickening levels, so in the same amount, 
the resulting thickness was different. The ease of pouring test 
illustrated it off from the bottle. Formula A has an average pouring 
time 2.31 seconds while formula B has 2.13 seconds. The less 
viscosity, the faster pouring time, because the fluidity of a solution is 
inversely proportional to viscosity [14]. The pH test showed that 
both formula A and formula B syrup have an average acidity level of 
4.51. This was because the buffer has maintained the acidity level of 
the syrup. The microbial number test result from each formula was 
still entering the range required by BPOM RI. Formula A has amount 
of yeast molds 440 colonies/ml while formula B has 140 
colonies/ml, from the requirements less than 1.000 colonies/ml. and 
total plate number, Formula A has amount of total plate 50 
colonies/ml while formula B has 100 colonies/ml, from the 
requirements less than 10.000 colonies/ml have the microbial 
number that was still fulfill the BPOM RI requirements [12] shown in 
table 2. Formula B syrup changed significantly since cycle 1, this was 
characterized by a decrease in viscosity, pouring power and up and 
down pH values that appear in fig. 1, 2 and 3. While formula A has 
the same viscosity from cycle 0 to cycle 3 ends. Therefore, formula A 
is more stable based on physical and microbiological parameters 
under extreme temperature treatment. The SPFN solution and SPFN 
syrup can significantly increase lymphocyte cell proliferation. 
Standardized polysaccharide fraction of Noni fruit showed a 
significant increase at concentration 53.32 μg/μl. The highest level 
of lymphocyte cell proliferation showed at a concentration of 106.64 
μg/μl. This showed an increase of lymphocyte cells were affected by 
the concentration of the polysaccharide fraction. Based on the 
results of statistical analysis, there was no significant difference 
between the OD of SPFN solutions in the majority of the 
polysaccharide fraction concentration. Therefore, the formulation 
does not affect the immunostimulant activity of syrup. The OD values 
of FTC solution showed significant differences at concentration of 
13.33 μg/μl; 53.32 μg/μl and 79.98 μg/μl respectively, while the OD 
values of FTC syrup did not show a significant difference in all 
concentrations. Therefore, the SPFN syrup is more stable in its 
immunostimulant activity compared to SPFN solution. This 
phenomenon showed that formula A of polysaccharide fraction into 
syrup with formula A, stable physically, microbial number and 
immunostimulant activity. Therefore, the SPFN syrup was more stable 
in its immunostimulant activity compared to the SPFN solution. This 
phenomenon showed that formulation of polysaccharide fraction into 
syrup form was more stable in physically, microbiology and 
immunostimulatory activity. 
CONCLUSION 
Formula A could be used to produce SPFN syrup which has a stable 
physical properties and immunostimulant activity beside no 
microbial contamination that fulfill requirements of BPOM RI 
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